Wyeth Pakistan Limited (Wyeth Pakistan) is a pubicaly held pharmaceutical company. The company is engaged in the manufacturing and marketing of research-based ethical specialties and other pharmaceutical products. Wyeth Pakistan launched two products named tygacil and premarin. Tygacil is found to be effective in the treatment of infections caused by susceptible strains of the designated micro-organisms, while premarin (conjugated estrogens) provides hormone therapy to the women for the treatment of menopausal symptoms. In addition, the company also includes products such as Advil, Caltrate, Centrum, ChapStick, Dimetapp and Robitussin. The company sells its products across Pakistan, Philippines, Kuwait and Sri Lanka. Wyeth Pakistan Limited is now the subsidiary of Pfizer Inc. The company is headquartered in Karachi, Pakistan. ( http://www.companyprofilesandconferences.com/report/Wyeth-Pakistan-Limited-WYETH-Financial-and-Strategic-SWOT-Analysis-Review.html )
This comprehensive SWOT profile of Wyeth Pakistan Limited provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalDatas Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, GlobalDatas highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Wyeth Pakistan Limited including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).